Treatment options for acute depression in bipolar disorder

Bipolar Disorders

Volumn 14, Issue SUPPL.2, 2012, Pages 37-50

  Bauer, Michael ^a   Ritter, Philipp ^a   Grunze, Heinz ^b   Pfennig, Andrea ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Anticonvulsants; Atypical antipsychotics; Bipolar disorder; Depression; Lithium; Pharmacotherapy; Psychotherapy

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ARIPIPRAZOLE; CARBAMAZEPINE; FLUOXETINE; IMIPRAMINE; LAMOTRIGINE; LITHIUM; MOCLOBEMIDE; OLANZAPINE; PAROXETINE; QUETIAPINE; SERTRALINE; TRANYLCYPROMINE; VALPROIC ACID; VENLAFAXINE;

BIPOLAR DEPRESSION; BIPOLAR I DISORDER; CONSTIPATION; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; FAMILY HISTORY; HEADACHE; HUMAN; INSOMNIA; LITHIUM BLOOD LEVEL; MANIA; NAUSEA; NERVOUSNESS; PERSONALITY; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOEDUCATION; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDE ATTEMPT; TREATMENT PLANNING; TREMOR; VAGUS NERVE STIMULATION; XEROSTOMIA;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; DEPRESSION; HUMANS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84859814946     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2012.00991.x     Document Type: Review

References (66)

1. Perlis RH, Dennehy EB, Miklowitz DJ et al. Retrospective age at onset of bipolar disorder and outcome during two-year follow-up: results from the STEP-BD study. Bipolar Disord 2009; 11: 391-400.
2. Bauer M, Glenn T, Rasgon N et al. Association between age of onset and mood in bipolar disorder: comparison of subgroups identified by cluster analysis and clinical observation. J Psychiatr Res 2010; 44: 1170-1175.
3. Baldessarini RJ, Tondo L, Hennen J. Treatment-latency and previous episodes: relationships to pretreatment morbidity and response to maintenance treatment in bipolar I and II disorders. Bipolar Disord 2003; 5: 169-179.
4. Ghaemi SN, Boiman EE, Goodwin FK. Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study. J Clin Psychiatry 2000; 61: 804-808.
5. Perlis RH, Miyahara S, Marangell LB et al. Long-term implications of early onset in bipolar disorder: data from the first 1000 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2004; 55: 875-881.
6. Beesdo K, Höfler M, Leibenluft E, Lieb R, Bauer M, Pfennig A. Mood episodes and mood disorders: patterns of incidence and conversion in the first three decades of life. Bipolar Disord 2009; 11: 637-649.
7. Goodwin GM, Anderson I, Arango C et al. ECNP consensus meeting. Bipolar depression. Nice, March 2007. Eur Neuropsychopharmacol 2008; 18: 535-549.
8. Novick DM, Swartz HA, Frank E. Suicide attempts in bipolar I and bipolar II disorder: a review and meta-analysis of the evidence. Bipolar Disord 2010; 12: 1-9.
9. Goodwin FK, Jamison KR. Course and outcome. In: Manic-Depressive Illness - Bipolar Disorders and Recurrent Depression. New York: Oxford University Press, 2007: 119-154.
10. Baldessarini RJ, Pompili M, Tondo L. Suicide in bipolar disorder: Risks and management. CNS Spectr 2006; 11: 465-471.
11. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009; 23: 346-388.
12. Yatham LN, Kennedy SH, Schaffer A et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009; 11: 225-255.
13. Malhi GS, Bargh DM, McIntyre R et al.. Balanced efficacy, safety, and tolerability recommendations for the clinical management of bipolar disorder. Bipolar Disord 2012; 14 (Suppl. 2): 1-21.
14. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002; 68: 167-181.
15. Colom F, Vieta E, Daban C, Pacchiarotti I, Sanchez-Moreno J. Clinical and therapeutic implications of predominant polarity in bipolar disorder. J Affect Disord 2006; 93: 13-17.
16. Frye MA. Clinical practice. Bipolar disorder-a focus on depression. N Engl J Med 2011; 364: 51-59.
17. Sachs GS. Treatment-resistant bipolar depression. Psychiatr Clin North Am 1996; 19: 215-236.
18. Yatham LN, Calabrese JR, Kusumakar V. Bipolar depression: criteria for treatment selection, definition of refractoriness, and treatment options. Bipolar Disorder 2003; 5: 85-97.
19. Malhi GS, Bargh DM, Cashman E, Frye MA, Gitlin M. The clinical management of Bipolar Disorder complexity using a stratified model. Bipolar Disord 2012; 14 (Suppl. 2): 66-89.
20. Grunze H, Vieta E, Goodwin GM et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010; 11: 81-109.
21. National Institute for Health and Clinical Excellence. Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Clinical Practice Guideline Number 38. London: The British Psychological Society, 2006.
22. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001; 134: 657-662.
23. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. DMW 2011; 136: 26.
24. Atkins D, Best D, Briss PA et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
25. Strech D, Soltmann B, Weikert B, Bauer M, Pfennig A. Quality of reporting of randomized controlled trials of pharmacologic treatment of bipolar disorders: a systematic review. J Clin Psychiatry 2011; 72: 1214-1221.
26. Pfennig A, Weikert B, Falkai P et al. Development of the evidence-based S3 guideline for diagnosis and therapy of bipolar disorders. Nervenarzt 2008; 79: 500-504.
27. Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989; 4: 313-322.
28. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148: 910-916.
29. Silverstone T. Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial. Acta Psychiatr Scand 2001; 104: 104-109.
30. Amsterdam JD, Shults J. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. J Clin Psychopharmacol 2008; 28: 171-181.
31. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007; 356: 1711-1722.
32. Leverich GS, Altshuler LL, Frye MA et al.. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006; 163: 232-239.
33. Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry 2000; 157: 124-126.
34. Bocchetta A, Bernardi F, Burrai C, Pedditzi M, Del ZM. A double-blind study of L-sulpiride versus amitriptyline in lithium-maintained bipolar depressives. Acta Psychiatr Scand 1993; 88: 434-439.
35. Tohen M, Vieta E, Calabrese J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079-1088.
36. Brown EB, McElroy SL, Keck PE Jr et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006; 67: 1025-1033.
37. McElroy SL, Weisler RH, Chang W et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 2010; 71: 163-174.
38. Bauer M, Zaninelli R, Muller-Oerlinghausen B, Meister W. Paroxetine and amitriptyline augmentation of lithium in the treatment of major depression: a double-blind study. J Clin Psychopharmacol 1999; 19: 164-171.
39. Pilhatsch M, Wolf R, Winter C, Lewitzka U, Bauer M. Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: A reanalysis of a randomized, double-blind study. J Affect Disord 2010; 126: 453-457.
40. Suppes T, Marangell LB, Bernstein IH et al. A single blind comparison of lithium and lamotrigine for the treatment of bipolar II depression. J Affect Disord 2008; 111: 334-343.
41. van der Loos ML, Mulder PG, Hartong EG et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70: 223-231.
42. Young AH, McElroy SL, Bauer M, Philips N et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 2010; 71: 150-162.
43. Zhang ZJ, Kang WH, Tan QR et al. Adjunctive herbal medicine with carbamazepine for bipolar disorders: A double-blind, randomized, placebo-controlled study. J Psychiatr Res 2007; 41: 360-369.
44. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79-88.
45. Calabrese JR, Keck PE Jr, Macfadden W et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351-1360.
46. Thase ME, Macfadden W, Weisler RH et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006; 26: 600-609.
47. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 2010; 121: 106-115.
48. Thase ME, Jonas A, Khan A et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008; 28: 13-20.
49. Miklowitz DJ, Otto MW, Frank E et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry 2007; 64: 419-426.
50. Ciapparelli A, Dell'Osso L, Tundo A et al. Electroconvulsive therapy in medication-nonresponsive patients with mixed mania and bipolar depression. J Clin Psychiatry 2001; 62: 552-555.
51. Nahas Z, Kozel FA, Li X, Anderson B, George MS. Left prefrontal transcranial magnetic stimulation (TMS) treatment of depression in bipolar affective disorder: a pilot study of acute safety and efficacy. Bipolar Disord 2003; 5: 40-47.
52. Nierenberg AA, Alpert JE, Gardner-Schuster EE, Seay S, Mischoulon D. Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depression. Biol Psychiatry 2008; 64: 455-460.
53. George MS, Rush AJ, Marangell LB et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry 2005; 58: 364-373.
54. Krauss SS, Depue RA, Arbisi PA, Spoont M. Behavioral engagement level, variability, and diurnal rhythm as a function of bright light in bipolar II seasonal affective disorder: an exploratory study. Psychiatry Res 1992; 43: 147-160.
55. Smeraldi E, Benedetti F, Barbini B, Campori E, Colombo C. Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression. A placebo-controlled trial. Neuropsychopharmacology 1999; 20: 380-385.
56. Benedetti F, Colombo C, Barbini B, Campori E, Smeraldi E. Ongoing lithium treatment prevents relapse after total sleep deprivation. J Clin Psychopharmacol 1999; 19: 240-245.
57. Benedetti F, Barbini B, Lucca A, Campori E, Colombo C, Smeraldi E. Sleep deprivation hastens the antidepressant action of fluoxetine. Eur Arch Psychiatry Clin Neurosci 1997; 247: 100-103.
58. Gershon S, Chengappa KNR, Malhi GS. Lithium specificity in bipolar illness: a classic agent for the classic disorder. Bipolar Disord 2009; 11 (Suppl. 2): 34-44.
59. Malhi GS, Tanious M. Optimal frequency of lithium administration in the treatment of bipolar disorder: clinical and dosing considerations. CNS Drugs 2011; 25: 289-298.
60. Malhi GS, Tanious M, Gershon S. The lithiumeter: a measured approach. Bipolar Disord 2011; 13: 219-226.
61. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009; 194: 4-9.
62. Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005; 85: 259-266.
63. Ghaemi SN, Gilmer WS, Goldberg JF et al.. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry 2007; 68: 1840-1844.
64. Cookson J, Keck PE Jr, Ketter TA, Macfadden W. Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study. Int Clin Psychopharmacol 2007; 22: 93-100.
65. Weisler RH, Calabrese JR, Thase ME et al. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry 2008; 69: 769-782.
66. Endicott J, Rajagopalan K, Minkwitz M, Macfadden W. A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life. Int Clin Psychopharmacol 2007; 22: 29-37.